Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics
TNGX Price/Volume Stats
| Current price | $7.44 | 52-week high | $13.03 |
| Prev. close | $7.33 | 52-week low | $2.47 |
| Day low | $7.26 | Volume | 301,900 |
| Day high | $7.50 | Avg. volume | 642,844 |
| 50-day MA | $9.05 | Dividend yield | N/A |
| 200-day MA | $8.56 | Market Cap | 794.11M |
TNGX Stock Price Chart Interactive Chart >
Tango Therapeutics, Inc. (TNGX) Company Bio
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Latest TNGX News From Around the Web
Below are the latest news stories about TANGO THERAPEUTICS INC that investors may wish to consider to help them evaluate TNGX as an investment opportunity.
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking plac |
Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business UpdatesAdvancing Precision Oncology: Tango Therapeutics Highlights Clinical Progress and Financial Health |
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nexte |
Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 1:00 PM GMT. A live webcast of the presentation will be available under the "Even |
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts. Abstracts accepted for poster presentation Title: |
TNGX Price Returns
| 1-mo | -6.30% |
| 3-mo | -35.47% |
| 6-mo | -10.58% |
| 1-year | 118.82% |
| 3-year | -35.47% |
| 5-year | N/A |
| YTD | -24.85% |
| 2023 | 36.55% |
| 2022 | -33.73% |
| 2021 | -4.37% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...